Adjuvant Treatment for Resected Stage IIIA–D Cutaneous Melanoma, BRAF Wild-Type (No BRAF V600E/K Mutation)

Clinical Scenario

This protocol addresses patients with resected stage IIIA–D cutaneous melanoma whose tumour is confirmed BRAF wild-type — no BRAF V600E or V600K mutation is present. After surgical resection, these patients require structured evaluation for adjuvant systemic therapy.

Adjuvant Therapy Approach

In BRAF wild-type resected stage IIIA–D melanoma, evidence-based adjuvant immunotherapy with specific checkpoint inhibitor agents is the recommended path. Certain other immunotherapy options are not recommended for routine use in this setting. The full selection of agents, scheduling considerations, and guidance on which therapies to avoid are detailed in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1200/JCO.23.01136

For patients with resected stage IIIA-D disease that is BRAF wild-type, the following adjuvant therapy options should be offered (in no particular order): nivolumab 3 52 weeks OR pembrolizumab 3 52 weeks.
Ipilimumab and high-dose IFN are not recommended for routine use in adjuvant therapy.

View source ↗